AIRLINK 191.84 Decreased By ▼ -1.66 (-0.86%)
BOP 9.87 Increased By ▲ 0.23 (2.39%)
CNERGY 7.67 Increased By ▲ 0.14 (1.86%)
FCCL 37.86 Increased By ▲ 0.16 (0.42%)
FFL 15.76 Increased By ▲ 0.16 (1.03%)
FLYNG 25.31 Decreased By ▼ -0.28 (-1.09%)
HUBC 130.17 Increased By ▲ 3.10 (2.44%)
HUMNL 13.59 Increased By ▲ 0.09 (0.67%)
KEL 4.67 Increased By ▲ 0.09 (1.97%)
KOSM 6.21 Increased By ▲ 0.11 (1.8%)
MLCF 44.29 Increased By ▲ 0.33 (0.75%)
OGDC 206.87 Increased By ▲ 3.63 (1.79%)
PACE 6.56 Increased By ▲ 0.16 (2.5%)
PAEL 40.55 Decreased By ▼ -0.43 (-1.05%)
PIAHCLA 17.59 Increased By ▲ 0.10 (0.57%)
PIBTL 8.07 Increased By ▲ 0.41 (5.35%)
POWER 9.24 Increased By ▲ 0.16 (1.76%)
PPL 178.56 Increased By ▲ 4.31 (2.47%)
PRL 39.08 Increased By ▲ 1.01 (2.65%)
PTC 24.14 Increased By ▲ 0.07 (0.29%)
SEARL 107.85 Increased By ▲ 0.61 (0.57%)
SILK 0.97 No Change ▼ 0.00 (0%)
SSGC 39.11 Increased By ▲ 2.71 (7.45%)
SYM 19.12 Increased By ▲ 0.08 (0.42%)
TELE 8.60 Increased By ▲ 0.36 (4.37%)
TPLP 12.37 Increased By ▲ 0.59 (5.01%)
TRG 66.01 Increased By ▲ 1.13 (1.74%)
WAVESAPP 12.78 Increased By ▲ 1.15 (9.89%)
WTL 1.70 Increased By ▲ 0.02 (1.19%)
YOUW 3.95 Increased By ▲ 0.10 (2.6%)
BR100 11,930 Increased By 162.4 (1.38%)
BR30 35,660 Increased By 695.9 (1.99%)
KSE100 113,206 Increased By 1719 (1.54%)
KSE30 35,565 Increased By 630.8 (1.81%)

KARACHI: Lucky Core Industries Limited (LCI) is pleased to announce that on May 17, the company executed Asset Purchase Agreements with Pfizer Pakistan Limited and Pfizer Inc., a leading global pharmaceutical group, for the acquisition of certain assets.

The assets being acquired by LCI through this transaction include a manufacturing facility owned by Pfizer Pakistan Limited located in Karachi, along with a portfolio of well-established pharmaceutical brands, namely Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D and Mycitracin, as well as trademarks associated with the said pharmaceutical products (either through an outright assignment of trademarks or a perpetual license to use the relevant trademarks). These leading brands are primary care products in the therapeutic areas including, pain, skin infections, and vitamin deficiencies, and have strong potential for growth in the market.

Chief Executive LCI, Asif Jooma, commented: “This acquisition marks a significant milestone in our journey towards accelerating growth of our Pharmaceuticals business. By adding these established brands to our portfolio, we will further enrich the lives of those around us by continuing to deliver quality medicines and healthcare products, while expanding our manufacturing base, diversifying our product offerings, and implementing synergies to strengthen our position in the marketplace.”

Copyright Business Recorder, 2024

Comments

Comments are closed.